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ABSTRACT
OBJECTIVE
To evaluate and compare benefits and harms of three 
biological treatments with different modes of action 
versus active conventional treatment in patients with 
early rheumatoid arthritis.
DESIGN
Investigator initiated, randomised, open label, 
blinded assessor, multiarm, phase IV study.
SETTING
Twenty nine rheumatology departments in Sweden, 
Denmark, Norway, Finland, the Netherlands, and 
Iceland between 2012 and 2018.
PARTICIPANTS
Patients aged 18 years and older with treatment 
naive rheumatoid arthritis, symptom duration less 
than 24 months, moderate to severe disease activity, 
and rheumatoid factor or anti-citrullinated protein 
antibody positivity, or increased C reactive protein.
INTERVENTIONS
Randomised 1:1:1:1, stratified by country, sex, 
and anti-citrullinated protein antibody status. 
All participants started methotrexate combined 
with (a) active conventional treatment (either 
prednisolone tapered to 5 mg/day, or sulfasalazine 
combined with hydroxychloroquine and intra-
articular corticosteroids), (b) certolizumab pegol, (c) 
abatacept, or (d) tocilizumab.
MAIN OUTCOME MEASURES
The primary outcome was adjusted clinical disease 
activity index remission (CDAI≤2.8) at 24 weeks with 
active conventional treatment as the reference. Key 
secondary outcomes and analyses included CDAI 
remission at 12 weeks and over time, other remission 
criteria, a non-inferiority analysis, and harms.
RESULTS
812 patients underwent randomisation. The mean 
age was 54.3 years (standard deviation 14.7) and 
68.8% were women. Baseline disease activity 
score of 28 joints was 5.0 (standard deviation 1.1). 
Adjusted 24 week CDAI remission rates were 42.7% 
(95% confidence interval 36.1% to 49.3%) for active 
conventional treatment, 46.5% (39.9% to 53.1%) 
for certolizumab pegol, 52.0% (45.5% to 58.6%) 
for abatacept, and 42.1% (35.3% to 48.8%) for 
tocilizumab. Corresponding absolute differences 
were 3.9% (95% confidence interval −5.5% to 
13.2%) for certolizumab pegol, 9.4% (0.1% to 
18.7%) for abatacept, and −0.6% (−10.1% to 8.9%) 
for tocilizumab. Key secondary outcomes showed 
no major differences among the four treatments. 
Differences in CDAI remission rates for active 
conventional treatment versus certolizumab pegol 
and tocilizumab, but not abatacept, remained within 
the prespecified non-inferiority margin of 15% (per 
protocol population). The total number of serious 
adverse events was 13 (percentage of patients who 
experienced at least one event 5.6%) for active 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Rheumatoid arthritis is associated with joint destruction, pain, functional 
impairment, and increased comorbidity and mortality
The optimal first line treatment has been debated, especially whether it should 
include a biological disease modifying drug
With multiple biological treatments, whose benefits and harms have not 
been compared in treatment naïve patients, it is unclear whether one or 
more biological drugs might be more beneficial or safer in patients with early 
rheumatoid arthritis
WHAT THIS STUDY ADDS
This trial compared the benefits and safety of three biological drugs with 
different modes of action, all given in combination with methotrexate, versus 
active conventional treatment in treatment naïve patients with rheumatoid 
arthritis
At 24 weeks, higher clinical disease activity index (CDAI) remission rate was 
observed for abatacept versus active conventional treatment (9.4%), but not for 
certolizumab pegol (3.9%) or tocilizumab (−0.6%) versus active conventional 
treatment
Non-inferiority analysis indicated that active conventional treatment was non-
inferior to certolizumab pegol and tocilizumab, but not to abatacept
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conventional treatment, 20 (8.4%) for certolizumab 
pegol, 10 (4.9%) for abatacept, and 10 (4.9%) for 
tocilizumab. Eleven patients treated with abatacept 
stopped treatment early compared with 20-23 
patients in the other arms.
CONCLUSIONS
All four treatments achieved high remission rates. 
Higher CDAI remission rate was observed for 
abatacept versus active conventional treatment, but 
not for certolizumab pegol or tocilizumab versus active 
conventional treatment. Other remission rates were 
similar across treatments. Non-inferiority analysis 
indicated that active conventional treatment was 
non-inferior to certolizumab pegol and tocilizumab, 
but not to abatacept. The results highlight the efficacy 
and safety of active conventional treatment based 
on methotrexate combined with corticosteroids, with 
nominally better results for abatacept, in treatment 
naive early rheumatoid arthritis.
TRIAL REGISTRATION
EudraCT2011-004720-35, NCT01491815.
Introduction
Rheumatoid arthritis is a chronic inflammatory joint 
disease associated with joint destruction, pain, 
functional impairment, and increased comorbidity and 
mortality.1 2 Early and active treatment is associated 
with improved outcome.3 The optimal first line 
treatment for patients with early rheumatoid arthritis 
has been debated, especially whether it should include 
a biological disease modifying drug.4 Currently, 
treatment recommendations in Europe and the United 
States advocate early treatment with conventional 
slow acting synthetic disease modifying drugs, with 
methotrexate as the anchor drug.4 5 The addition of 
short term low to moderate dose corticosteroids to 
methotrexate (termed active conventional treatment) 
might optimise results.4  6-8 Biological disease 
modifying antirheumatic drugs with different modes 
of action have been marketed. The most frequently 
used treatments prescribed early in the disease 
course are tumour necrosis factor α inhibition, T cell 
costimulation blocker, and interleukin 6 inhibition. 
Previous trials have shown superior outcomes in 
treatment naïve patients who have received biological 
drugs in combination with methotrexate compared 
with methotrexate and placebo.9-13 Several biological 
drugs are available whose benefits and harms need 
to be compared with one another in treatment naïve 
patients. Studies are needed to determine whether one 
or more biologicals might be more beneficial or safer, 
or better tailored to different subgroups of patients 
with rheumatoid arthritis. Therefore, a consortium 
of Scandinavian and Dutch academic investigators 
planned and conducted a randomised trial examining 
the comparative benefits and safety of biological 
drugs with different modes of action versus active 
conventional treatment in treatment naïve patients 
with rheumatoid arthritis.
In the first part of the NOrdic Rheumatic Diseases 
Strategy Trials And Registries (NORD-STAR) study 
our objective was to assess and compare the efficacy 
and safety after 24 weeks of active conventional 
treatment (either methotrexate combined with oral 
corticosteroids or methotrexate combined with intra-
articular corticosteroids and other conventional 
synthetic disease modifying antirheumatic drugs) 
versus three biological treatments: a tumour necrosis 
factor inhibitor (certolizumab pegol), a T cell 
costimulation blocker (abatacept), and an interleukin 
6 inhibitor (tocilizumab), all given in combination 
with methotrexate. Our hypothesis was that a higher 
clinical disease activity index (CDAI) remission rate 
would be observed for one or several of the biologicals 
compared with active conventional treatment.
Methods
Trial design and conduct
The design of this investigator initiated, multicentre, 
randomised, open label, blinded assessor trial 
(ClinicalTrials.gov: NCT01491815) has been published 
previously.14 The protocol is included in the online 
supplementary files. The trial has two parts: initial 
randomisation to one of four different treatment arms 
aiming to achieve remission (up to 80 weeks’ follow-
up); and rerandomisation to two different tapering 
strategies of patients who reach the remission target. 
We present the 24 week analyses of the primary clinical 
outcome and key secondary outcomes. A steering 
committee of academic investigators designed and 
oversaw the trial. They also analysed and interpreted 
the data and contributed to the manuscript. We 
report our findings in accordance with the CONSORT 
(Consolidated Standards of Reporting Trials) 
statements, including the extension for multiarm, 
parallel group randomised trials.15-17
Study population
The trial population consisted of patients with early 
rheumatoid arthritis according to the American 
College of Rheumatology and European League 
Against Rheumatism (ACR/EULAR) 2010 classification 
criteria.18 Key inclusion criteria were age 18 years or 
older, symptom duration less than 24 months, moderate 
to severe disease activity with disease activity score 
(DAS28) greater than 3.2 (DAS28 calculated from 28 
swollen and tender joint counts, patient global score, 
and C reactive protein), at least two (of 66) swollen and 
at least two (of 68) tender joints, and rheumatoid factor 
or anti-citrullinated protein antibody positivity (ACPA), 
or C reactive protein at least 10 mg/L. Key exclusion 
criteria included previous treatment with disease 
modifying antirheumatic drugs. Table S1 provides 
details about the inclusion and exclusion criteria.
Randomisation and interventions
Patients were randomised 1:1:1:1, stratified by 
country, sex, and ACPA status. Randomisation was 
done through the trial centre at the Karolinska 
Institute (see supplementary appendix for details). 
All patients started methotrexate on day 1 (escalated 
within four weeks to 25 mg every week) with folic 
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acid supplementation (minimum 5 mg every week) 
combined with one of the following:
• Arm 1 (active conventional treatment)—either (a) 
oral prednisolone (tapered from 20 to 5 mg/day 
in nine weeks); or (b) enterotablets sulfasalazine 
(2 g/day) combined with hydroxychloroquine (35 
mg/kg every week or 200 mg/day) and mandatory 
intra-articular triamcinolone hexacetonide 
injection (or equivalent) in all swollen joints at 
each visit (maximally four joints and 80 mg every 
visit and no later than week 20)
• Arm 2 (certolizumab pegol)—200 mg every other 
week subcutaneously (loading dose 400 mg at 
week 0, 2, and 4)
• Arm 3 (abatacept)—125 mg every week 
subcutaneously
• Arm 4 (tocilizumab)—8 mg/kg every four 
weeks intravenously or 162 mg every week 
subcutaneously.
Intra-articular corticosteroid injections were allowed 
on demand up to week 20 in arm 1 and up to week 12 in 
arms 2-4; for details see protocol and statistical analysis 
plan in supplementary files.14 Patients received folate, 
vitamin D, and calcium supplementation according to 
local or national guidelines.
Trial outcomes and blinding
The primary clinical efficacy outcome was adjusted 
CDAI remission (defined as CDAI≤2.8) at week 24.19 
CDAI is calculated as the sum of swollen joint count 
(0-28), tender joint count (0-28), patient’s global score 
of disease activity (0-10), and investigator’s global 
score (0-10). An independent blinded assessor with no 
other roles in the study conducted the joint counts. Key 
secondary efficacy outcomes included CDAI remission 
at week 12 and over time (at week 4, 8, 12, 16, and 
24); and other remission criteria at week 12, week 24, 
and over time: ACR/EULAR Boolean criteria, DAS28 
and simplified disease activity index remission, and 
EULAR good response (see statistical analysis plan in 
supplementary files).20-23
Safety outcomes were the numbers and percentages 
of patients with serious and non-serious adverse events 
for each treatment arm. Predefined adverse events of 
interest included infections, cardiovascular disease, 
cataract, venous thromboembolism, demyelinating 
disease, diabetes mellitus, herpes zoster, malignancy, 
osteoporosis, tuberculosis, and weight gain. All safety 
events were MedDRA coded (version 22.0).
Statistical analysis
This was a phase IV trial done in a clinical setting, not a 
confirmatory phase III trial. Therefore, as prespecified 
in the statistical analysis plan, effect estimates 
and 95% confidence intervals are reported for the 
differences between treatment arms at specific time 
points. Formal hypothesis tests were not performed, 
and confidence limits were not adjusted for multiplicity 
(see the statistical framework and statistical analysis 
plan in supplementary files).
The a priori sample size calculation indicated that 
we needed to randomise 724-832 patients to detect an 
overall difference between the four treatment groups 
with a power of 85-90%, assuming CDAI remission 
rates of 12%, 22%, 22%, and 26% in the active 
conventional treatment, certolizumab pegol, abatacept, 
and tocilizumab arms, respectively9-11 24-28 (see protocol 
and statistical framework for details). We expected one 
or several of the three biological drugs to have higher 
remission rates than the active conventional treatment. 
The three comparisons were conducted in parallel, with 
inference made in each comparison.
The primary analysis population was the intention-
to-treat population, defined as all randomised patients 
except 17 Finnish patients, for whom allocated treatment 
(tocilizumab) was not available (see statistical analysis 
plan in supplementary files). Strictly interpreted, these 
patients should have remained in the intention-to-treat 
population with non-responder imputation. Instead, 
the steering committee decided before data lock to 
exclude them from the intention-to-treat population to 
allow a fair analysis of the efficacy of tocilizumab. For 
transparency, the results of the analyses conducted on 
the strict intention-to-treat population are presented in 
the supplementary appendix.
The primary analysis of the primary and secondary 
dichotomous outcomes was done using a logistic 
regression model, adjusted for sex, ACPA status, 
country, age, body mass index, and DAS28 at baseline, 
with missing remission status imputed with worst 
case (non-remission). We present adjusted average 
marginal differences in remission rates with 95% 
confidence intervals, estimated by the delta method. 
Robustness analyses were performed using unadjusted 
logistic regression and longitudinally using adjusted 
and unadjusted generalised estimating equations, 
accounting for within patient correlation. Generalised 
estimating equations used non-imputed data with an 
exchangeable correlation structure. Robustness analyses 
were also performed and included the 17 Finnish patients 
mentioned above. Continuous secondary outcomes 
were analysed using generalised linear mixed gamma 
(C reactive protein and erythrocyte sedimentation rate), 
negative binomial (joint counts), or normal models 
(other), all with random intercept adjusted for baseline 
characteristics and value. Some of the other secondary 
outcomes are not reported here; we will report them in a 
separate publication (table S15 gives details).
We conducted non-inferiority analyses in the per 
protocol population, which consisted of patients who 
received study drugs as planned, by predefining a margin 
of 15% based on previous trials (see statistical analysis 
plan and statistical framework in supplementary 
files).29 30 For safety outcomes, descriptive statistics 
were applied on the safety population.
Patient and public involvement
Patients or the public were not involved in the design, 
or conduct, or reporting of the study, but the patient 
organisations of the involved countries will be involved 
in the dissemination plans of our research.
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Results
Participants
From 3 December 2012 to 11 December 2018, 903 
patients were assessed for eligibility at 29 sites (listed 
in supplementary files). The proportion of screened 
patients who did not undergo randomisation was 
10% (91/903); 812 underwent randomisation (fig 
S1). The last 24 week visit was conducted on 28 May 
2019. Patient characteristics were well balanced 
(table 1). The mean age was 54.3 years, 68.8% of 
the patients were women, average symptom duration 
was 204 days, and mean time since diagnosis was 14 
days. Disease activity was moderate to severe, with an 
average DAS28 of 5.0 and CDAI of 28.0. Rheumatoid 
factor was positive in 74.7% of patients, while 81.9% 
were ACPA positive.
Efficacy outcomes
Table 2 summarises efficacy outcomes. The adjusted 
CDAI remission rate at 24 weeks was 42.7% (95% 
confidence interval 36.1% to 49.3%) for patients 
in the active conventional treatment group, 46.5% 
(39.9% to 53.1%) for the certolizumab pegol group, 
52.0% (45.5% to 58.6%) for the abatacept group, 
and 42.1% (35.3% to 48.8%) for the tocilizumab 
group. With active conventional treatment as the 
reference, the adjusted difference in CDAI remission 
rate was 3.9% (95% confidence interval −5.5% 
to 13.2%) for certolizumab pegol, 9.4% (0.1% to 
18.7%) for abatacept, and −0.6% (−10.1% to 8.9%) 
for tocilizumab. The adjusted CDAI remission rates at 
12 weeks were largely similar across treatments; with 
active conventional treatment as the reference, the 
remission rates were 4.5%, 2.6%, and 4.6% higher 
for certolizumab pegol, abatacept, and tocilizumab, 
respectively. The mean adjusted difference in CDAI 
remission over time was 6.3% (−0.4% to 12.9%) 
for certolizumab pegol, 1.5% (−5.0% to 7.9%) for 
abatacept, and 2.0% (−4.7% to 8.7%) for tocilizumab. 
Figure 1 shows that for adjusted CDAI remission 
rates over time no clear separation was found 
between the four treatment arms. For key secondary 
outcomes, results were generally similar across the 
four treatment groups (table 2, figs S3-S6). Table S2 
and figs S7-S13 present results for other secondary 
outcomes.
Robustness analyses
We conducted prespecified robustness analyses of 
the primary and key secondary efficacy outcomes. 
The results were consistent with those of the primary 
analyses (fig S14 and tables S3-S5).
Non-inferiority analyses
For CDAI remission at 24 weeks, differences in 
remission rates for the active conventional treatment 
versus certolizumab pegol and tocilizumab, but not 
abatacept, remained within the predefined non-
inferiority margin of 15% (fig 2). Tables S6-S7 show 
the results of the non-inferiority analyses.
Corticosteroids
The use of corticosteroids was mandatory in arm 1, 
either orally (bridging treatment with tapering, arm 
1A, n=137) or as mandatory injections of swollen 
joints (arm 1B, n=63). In arm 1A, prednisolone 
was reduced from 20 to 5 mg in nine weeks, then 
kept stable (5 mg) through week 32, then reduced 
and stopped at week 36. In arm 1B, from week 0 
to week 4 the cumulative dose of triamcinolone 
hexacetonide corresponded to a median of 50 mg 
(interquartile range 34-80 mg), increasing to a total of 
66 (40-94) mg by week 24. In the certolizumab pegol, 
abatacept, and tocilizumab arms the cumulative 
doses from week 0 to week 24 were 20 (0.0-80) mg, 
20 (0.0-80) mg, and 0.0 (0.0-40) mg triamcinolone 
hexacetonide, respectively. The median cumulative 
dose of triamcinolone hexacetonide corresponded to 
a daily dose of less than 1 mg prednisolone in arm 1B 
and less than 0.5 mg in the certolizumab pegol and 
abatacept arms under the assumption that 40 mg of 
triamcinolone is equivalent to 50 mg of prednisolone.
Safety outcomes and adherence to treatment
No suspected unexpected harms were reported. 
The percentages of patients who reported at least 
one adverse event in the groups receiving active 
conventional treatment, certolizumab pegol, 
abatacept, and tocilizumab were 86.3%, 82.7%, 
79.9%, and 95.1%, respectively (table 3); at least one 
serious adverse event was reported in 5.6%, 8.4%, 
4.9%, and 4.9% of patients, respectively. The number 
of patients who stopped treatment early was lowest for 
patients receiving abatacept (11 patients), compared 
with 20, 23, and 22 patients in the active conventional 
treatment, certolizumab pegol, and tocilizumab arms, 
respectively. Figure S1 gives the reasons for stopping 
treatment early.
Of the prespecified adverse events of interest, 
infections were reported in 34.5%, 36.6%, 34.3%, 
and 45.7% of patients treated with active conventional 
treatment, certolizumab pegol, abatacept, and 
tocilizumab, respectively. Harms associated with 
corticosteroid use (cataract, diabetes mellitus, 
osteoporosis, and weight gain) were rare (0-1.5% in 
all arms), and cardiovascular disease was reported in 
1.5%, 3.5%, 4.4%, and 3.3% of patients, respectively.
Gastrointestinal symptoms were reported in 42.1%, 
29.7%, 37.3%, and 29.9% of patients treated with 
active conventional treatment, certolizumab pegol, 
abatacept, and tocilizumab, respectively (table S14). 
Increased liver enzymes were reported in 10.7%, 
14.4%, 14.2%, and 30.4%, and increased neutropenia 
or leukopenia in 1%, 1%, 1.5%, and 12.5% of patients, 
respectively. For more details on harms, see tables S9-
S14.
Discussion
Statement of principal findings
We found that CDAI remission was achieved in 
more than 40% of patients with treatment naïve 
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early rheumatoid arthritis who were treated with 
biological drugs with different modes of action 
(certolizumab pegol, abatacept, or tocilizumab), which 
were all given in combination with methotrexate. 
Patients who received active conventional treatment 
(methotrexate combined with bridging treatment with 
corticosteroids, and in some patients also sulfasalazine 
and hydroxychloroquine) had comparable remission 
rates. With the active conventional treatment as the 
reference, abatacept performed 9% better in achieving 
CDAI remission (primary efficacy outcome). For all key 
secondary outcomes, including longitudinal analysis 
and a range of other remission and response criteria, 
the overall differences between treatments were modest 
with overlapping confidence intervals. A prespecified 
non-inferiority analysis of the primary outcome 
showed that active conventional treatment was non-
inferior to certolizumab pegol and tocilizumab, but 
not to abatacept. Among the prespecified harms of 
interest, serious adverse event rates were highest in the 
certolizumab pegol group, whereas infection rates and 
events of increased hepatic enzymes and neutropenia 
or leukopenia were higher in the tocilizumab arm. We 
found no increased risk of adverse events attributable 
to corticosteroid use in the active conventional 
treatment arm, whereas gastrointestinal symptoms 
were most common in this arm.
Strengths and weaknesses of the study
This randomised clinical trial examined the 
comparative benefits and safety of biological drugs with 
different modes of action versus active conventional 
Table 1 | Personal and clinical characteristics of patients at baseline (intention-to-treat population). Values are means 
(standard deviations) unless stated otherwise
Characteristic
Active conventional 
treatment (n=200)
Certolizumab pegol and 
methotrexate (n=203)
Abatacept and 
 methotrexate (n=204)
Tocilizumab and 
 methotrexate (n=188)
Age (years) 54.6 (14.5) 55.3 (15.3) 54.7 (14.4) 52.4 (14.5)
Women (n (%)) 139 (69.5) 139 (68.5) 140 (68.6) 129 (68.6)
Symptom duration (days) 195 (167) 203 (166) 212 (168) 208 (155)
Time since diagnosis (days) 13 (21) 12 (17) 16 (34) 16 (33)
Body mass index* 26.6 (5.4) 25.7 (4.9) 26 (4.9) 26.8 (5.1)
Non-smoker (n (%)) 80 (40) 76 (37.4) 77 (37.7) 85 (45.2)
Former smoker (n (%)) 85 (42.5) 79 (38.9) 78 (38.2) 60 (31.9)
Current smoker (n (%)) 35 (17.5) 47 (23.2) 49 (24) 43 (22.9)
Anti-citrullinated peptide antibody 
positive (n (%))
163 (81.5) 166 (81.8) 169 (82.8) 153 (81.4)
Rheumatoid factor positive (n (%)) 151 (75.5) 149 (73.4) 159 (77.9) 135 (71.8)
Clinical disease activity index (CDAI) 28.6 (12.1) 27.9 (12.4) 28.6 (11.3) 26.6 (11.7)
Disease activity score of 28 joints 
(CRP based)
5.1 (1.1) 5.0 (1.1) 5.1 (1) 4.9 (1)
Tender joint count (68 joints) 17 (11.4) 15.3 (10.4) 16.1 (10.7) 14.8 (10.2)
Swollen joint count (66 joints) 11.4 (7.3) 11.2 (7.6) 11.1 (7.3) 9.8 (6.4)
Patient’s global assessment of  
disease activity (mm)
56.7 (23.2) 56.6 (23.7) 60.4 (23.6) 57.4 (22.6)
Physician’s global assessment of 
disease activity (mm)
48.8 (19.2) 49.3 (19.2) 51.7 (18.7) 49.7 (18.1)
Patient’s assessment of pain (mm) 56 (24.2) 55.7 (24.7) 59.3 (24.2) 55.3 (23)
Health assessment questionnaire 
(0-3)
1.1 (0.6) 1 (0.6) 1.1 (0.6) 1.1 (0.5)
CRP=C reactive protein.
*Two patients had missing value for body mass index at baseline. The missing values were imputed with the median.
Table 2 | Primary and key secondary outcomes. Values are percentage differences in rates (95% confidence intervals) 
with active conventional treatment as reference
Parameter Week No
Certolizumab pegol and 
 methotrexate v active  
conventional treatment
Abatacept and  
methotrexate v active 
 conventional treatment
Tocilizumab and 
 methotrexate v active 
 conventional treatment
Primary outcome
CDAI remission 24 3.9 (−5.5 to 13.2) 9.4 (0.1 to 18.7) −0.6 (−10.1 to 8.9)
Key secondary outcomes
CDAI remission 12 4.5 (−4.4 to 13.3) 2.6 (−6.1 to 11.4) 4.6 (−4.4 to 13.7)
ACR/EULAR Boolean remission 24 3.6 (−5.7 to 12.9) 4.6 (−4.6 to 13.9) −3.8 (−13.2 to 5.6)
ACR/EULAR Boolean remission 12 7.1 (−1.3 to 15.6) 7.2 (−1.2 to 15.7) 9.2 (0.5 to 18)
DAS28 remission 24 2.6 (−6.2 to 11.4) 4.5 (−4.2 to 13.2) −0.7 (−9.8 to 8.4)
DAS28 remission 12 5.8 (−3.3 to 14.9) 2.2 (−6.9 to 11.3) 14 (4.8 to 23.1)
SDAI remission 24 6.4 (−3 to 15.7) 8.9 (−0.3 to 18.2) 1.4 (−8.1 to 10.9)
SDAI remission 12 6.9 (−2 to 15.7) 3.6 (−5.2 to 12.3) 7.5 (−1.5 to 16.6)
EULAR good response 24 4.4 (−4.1 to 12.8) 7.6 (−0.7 to 15.8) 0.4 (−8.4 to 9.2)
EULAR good response 12 7.3 (−1.3 to 16) 4.9 (−3.8 to 13.6) 10.4 (1.8 to 19.1)
ACR=American College of Rheumatology; CDAI=clinical disease activity index; DAS28=disease activity score of 28 joints (C reactive protein based, four 
variables); EULAR=European League Against Rheumatism; SDAI=simple disease activity index.
Primary analyses, intention-to-treat population, logistic regression analysis adjusted for baseline covariates. Marginal estimates averaged over the 
covariates as observed in the sample.
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treatment in treatment naïve patients with rheumatoid 
arthritis, and includes three different biological drugs. 
We consider the generalisability of our findings to be 
high because 90% of screened patients underwent 
randomisation, and the baseline characteristics 
were typical for treatment naïve patients with poor 
prognosis.
One limitation is that, although this was a large 
investigator initiated study in patients with early 
rheumatoid arthritis, it was not powered to directly 
compare the biological drugs to each other. Another 
limitation is the open label design, which could 
influence the decision to proceed in the trial after 
randomisation. Only two patients (one in arm 1 
and one in arm 4) withdrew informed consent after 
randomisation. The open label design, although partly 
offset by the use of blinded joint assessors, could 
influence certain subjective outcomes; expectation 
bias would probably have disfavoured the conventional 
treatment arm in this instance. Longer treatment follow-
up is needed for cardiovascular events, corticosteroid 
related safety outcomes, and structural damage; these 
will be assessed after 48 weeks.
Strengths and weaknesses in relation to other 
studies, discussing important differences in results
Our findings contrast with phase III trials that have 
consistently shown a minimum of 10-20% lower 
remission rates in the methotrexate alone arm.11-13 
Inspired by clinical practice (and in contrast to phase 
III trials), we used corticosteroids as bridging treatment 
because methotrexate is a slow acting drug. Some trials 
in treatment naïve patients with early rheumatoid 
arthritis have studied methotrexate combined with 
corticosteroids (orally or intra-articularly) as bridging 
treatment and shown good efficacy. However, 
these trials were without biological comparators, 
used biological treatment only as induction 
treatment, combined the biological comparator with 
corticosteroids, or used higher doses of corticosteroids 
and suboptimal doses of methotrexate.6 7 31-33
In the EXXELERATE study of methotrexate, which 
included insufficient responders with established 
rheumatoid arthritis, two tumour necrosis factor 
inhibitors were compared (certolizumab pegol 
and adalimumab) and no differences in efficacy 
were found.34 In the ORBIT trial,35 rituximab was 
non-inferior to tumour necrosis factor inhibitors 
(adalimumab or etanercept) in patients who were 
seropositive and had early rheumatoid arthritis, and 
insufficient response to synthetic disease modifying 
drugs. In the ATTEST and AMPLE trials, abatacept was 
compared with infliximab (a tumour necrosis factor 
inhibitor) and adalimumab, respectively, in patients 
with inadequate response to methotrexate and the 
efficacy of abatacept was similar to that of the tumour 
necrosis factor inhibitor.36 37 In agreement with our 
findings, abatacept had fewer discontinuations owing 
to adverse events than adalimumab.37
What the study adds in light of relevant systematic 
reviews and meta-analyses
A recent systematic review and network meta-analysis 
of methotrexate naïve patients mainly provided indirect 
comparisons of biologicals to each other.38 The authors 
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Fig 1 | Probability of clinical disease activity index (CDAI) remission over time for 
each treatment group. Longitudinal analysis on the intention-to-treat population 
using adjusted generalised estimating equations and accounting for within patient 
correlation. Average marginal estimates are shown, averaged over the covariates as 
observed in the sample. Bars indicate 95% confidence intervals
Active conventional treatment (reference)
Certolizumab pegol and methotrexate
Abatacept and methotrexate
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Fig 2 | Forest plot of risk differences. Estimated differences (95% confidence intervals) in clinical disease activity index (CDAI) remission rates at 
24 weeks between active conventional treatment and methotrexate in combination with certolizumab pegol, abatacept, or tocilizumab. Logistic 
regression analysis, adjusted for sex, anti-citrullinated protein antibody positivity status, country, age, body mass index and baseline disease 
activity score of 28 joints (C reactive protein based, four variables; marginal estimates averaged over covariates as observed in sample). Dashed line 
shows non-inferiority margin. Figure based on per protocol dataset
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concluded that moderate quality evidence was found 
that, compared with methotrexate alone, biologicals 
given in combination with methotrexate were associated 
with absolute and relative clinically meaningful benefits 
(15%) in DAS28 remission rates, and no higher risk 
of serious adverse events existed compared with 
methotrexate. Other systematic reviews and network 
meta-analyses looking at the comparative effectiveness 
of biological drugs have mainly focused on patients with 
disease that has failed to respond to methotrexate.39
Meaning of the study: possible explanations and 
implications for clinicians and policy makers
The primary clinical outcome was CDAI remission at 
24 weeks, a more stringent remission criterion than 
the DAS28 based criterion, which has traditionally 
been used in many trials. We chose the CDAI because 
the algorithm does not include acute phase reactants, 
which are differentially impacted upon by different 
biological treatments.
National preferences on the exact implementation 
of active conventional treatment were reflected in 
slightly different strategies in Denmark and Finland 
(triple treatment with methotrexate, sulfasalazine, and 
hydroxychloroquine combined with intra-articular 
triamcinolone hexacetonide) versus Sweden, Norway, 
the Netherlands, and Iceland (methotrexate combined 
with 20 mg prednisolone initially, tapered to 5 mg after 
nine weeks and discontinued after nine months). The 
active conventional treatment strategy with bridging 
corticosteroid brought promising results until week 
24; the clinical results at week 48 will inform us if this 
is sustainable in the long term.
Abatacept had fewest discontinuations, which 
contributed to its higher remission rate, because 
patients who stopped treatment early were imputed as 
non-responders. This finding emphasises the role of 
tolerability and harms in the evaluation of drug efficacy.
Unanswered questions and future research
The study is ongoing. Follow-up at 48 weeks will show 
long term efficacy, and structural damage and harms for 
each of the four treatments. The second part of the trial 
will assess and compare two alternative de-escalation 
strategies in patients who have achieved remission. 
Research projects based on the NORD-STAR biobank will 
inform us whether one or more of the biological drugs 
might be better tailored to different subgroups of patients.
Conclusion
High remission rates were found in disease 
modifying antirheumatic drug naïve patients with 
early rheumatoid arthritis who started treatment 
with methotrexate in combination with abatacept, 
certolizumab pegol, tocilizumab, or active conventional 
treatment. We observed higher CDAI remission rates 
for abatacept versus active conventional treatment, 
but not for certolizumab pegol or tocilizumab versus 
active conventional treatment. Other remission rates 
were similar across treatments. Non-inferiority analysis 
indicated that active conventional treatment was non-
inferior to certolizumab pegol and tocilizumab, but 
not to abatacept. Rates of adverse events and early 
withdrawals were lowest for abatacept. The results 
highlight the efficacy and safety of active conventional 
treatment based on methotrexate combined with 
corticosteroids, with nominally better results for 
abatacept, in treatment naive early rheumatoid arthritis.
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†No events were coded as venous thromboembolism and tuberculosis. Osteoporosis events were reported shortly after baseline, based on, for example, 
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